MoonLake Immunotherapeutics (MLTX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Zug, スイス. 現CEOは Jorge Santos da Silva.
MLTX を有する IPO日 2020-10-20, 100 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $1.35B.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
